Search Results : Human Genome Sciences
Blog Post Results (101-120 of 305)
This Just In: More Upgrades and Downgrades
New ratings for Level 3 Communications, Vivus, and Human Genome Sciences.
Larry Bock: Exploring Deep, Mysterious Realms With Time Warp Scientist Jeff Lieberman
With the human genome decoded, science is poised now to set sights on a more ethereal realm: human consciousness, one of the least understood facets of human cognition.
Tiny Thumb Drive Can Decode an Entire Human Genome in Six Hours [Science]
It was a major breakthrough in 1995: After 13 months, scientists 13 finally sequenced the entire genome of a bacteria. More »
SCIENCE: Entire genome of extinct human decoded from fossil. “The genome represents the first high…
SCIENCE: Entire genome of extinct human decoded from fossil. “The genome represents the first high-coverage, complete genome sequence of an archaic human group – a leap in the study of extinct forms of humans.”
A Bio-Pharma Buy And Sell List: Part 2
By Scott Matusow: In Part 1 of this two part article, I gave a quick opinion on the following bio-Pharmas: Human Genome Sciences (HGSI) Arena Pharmaceuticals (ARNA) Vivus Inc. (VVUS), Idenix Pharmaceuticals (IDIX) Inhibitex Inc. (INHX) Here in Part 2, I will give a quick summary of a few more bio-pharmas followed by my opinion and some comments. Show More Summary
Short Covering Sparks HGSI Price Spike
By VFC: After briefly spiking during last year's closing months on a positive sales update for Benlysta and takeover chatter from across the pond, the heavily shorted shares of Human Genome Sciences (HGSI) dropped to below seven dollars at one point, before closing 2011 at just over that mark. Show More Summary
Human Genome Sciences Rockets 14% on Positive Comments
Piper Jaffray cut its Benlysta sales estimates for Human Genome...
Linear Growth Isn't Enough
Human Genome Sciences needs to accelerate growth.
Human Genome Might Have Bottomed
By Prohost Biotech: As expected, Human Genome Sciences (HGSI) will report on progress with the commercialization of Benlysta® (belimumab) during a presentation at the 30th Annual JPMorgan Healthcare Conference in San Francisco. The drug...Show More Summary
Biotech Investors Buoyed By Signs Of Speedier Drug Launches
By EP Vantage: Can Dendreon’s (DNDN) better-than-expected 2011 sales numbers be taken as a good omen for Human Genome Sciences (HGSI) and other companies struggling with new product launches (HGS suffers the launch blues as BenlystaShow More Summary
A Bad Year for the 6,300% Miracle
Human Genome Sciences falls from grace.
Analyzing Pharmaceutical Strategic Alliances
By VFC: The collaboration between Human Genome Sciences (HGSI) and GlaxoSmithKline (GSK) continues. The two partners were the first to bring a new lupus-treating drug to market in over fifty years with Benlysta earlier this year, and the pipeline development continues as the two companies announced this week the initiation of another Phase III trial. Show More Summary
Following Digital Breadcrumbs To Big Data Gold
Following Digital Breadcrumbs To 'Big Data' Gold What do Facebook, Groupon and biotech firm Human Genome Sciences have in common? They all rely on massive amounts of data to design their products. Terabytes and even zettabytes of information...Show More Summary
Stocks To Watch This Week
By VFC: Some stocks and stories to watch for this week... HGSI: Shares of Human Genome Sciences (HGSI) have quickly retreated following a spike last month on buyout rumors that originated in England. A sub par earnings release started...Show More Summary
Cramer's Mad Money - The Most Inexpensive Growth Stock I Follow (11/16/11)
By Miriam Metzinger: Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday November 16. Which Is Cheaper, Pfizer (PFE) or Celgene (CELG)? Other stock mentioned: Human Genome Sciences (HGSI) The wayShow More Summary
UK Patent Case Lowers Bar on Utility (Industrial Application)
Human Genome Sciences v. Eli Lilly (UK Supreme Court, 2 Nov 2011) [Decision] Case No. [2011] UKSC 51. The Supreme Court of the United Kingdom (UKSC) began hearing cases in 2009 — taking on the role of court-of-last-resort formerly played...
Is Intel Inside Your Portfolio?
By Helix Investment Management: At Helix Investment Management, we own stocks that are of all stripes. From fast growers like Chipotle and Apple, to speculative biotechs like Human Genome Sciences, to defensive names like Costco and UPS. Show More Summary
Attention On Human Genome As Speculation, Media Influences Come Into Play
By VFC: Interest has been all over Human Genome Sciences (HGSI) lately since a rumor originated from across the pond in mid October that GlaxoSmithKline (GSK), HGSI's marketing partner for the lupus-fighting Benlysta, was considering a buyout of its smaller American partner. Show More Summary
Human Genome Dropping Again With So-So Earnings
By VFC: Shares of Human Genome Sciences (HGSI) are trading back to earth this week after having hit the fifteen dollar mark on talk of a buyout by Benlysta GlaxoSmithKline (GSK) last week. When the buyout talk, which originated in the...Show More Summary